Evogene Cuts Costs, Expands AI Capabilities in Strategic Pivot
Event summary
- Evogene reduced its workforce from 117 employees in December 2024 to 38 in August 2026 as part of its strategic transformation.
- The company expects full-year 2026 cash usage to be approximately $8.5 million to $9.5 million, down from $20.5 million in 2024.
- Evogene expanded its virtual chemical space to approximately 110 billion molecules, supported by advanced AI models and autonomous AI Agents.
- Six active drug development collaborations established with biotechnology companies and leading academic institutions.
- Evogene received approximately $2.9 million from Lavie Bio's dividend distribution during the second quarter.
The big picture
Evogene's strategic transformation reflects a broader industry trend toward AI-driven computational chemistry, aiming to streamline operations and reduce costs while maintaining innovation. The company's focus on high-value programs and strategic partnerships aligns with market dynamics favoring efficiency and technological advancement in biotechnology and agriculture.
What we're watching
- Cost Reduction
- Whether Evogene can sustain its reduced cash burn rate while advancing its drug development and agricultural programs.
- AI Expansion
- The pace at which Evogene can integrate and scale its expanded virtual chemical space and autonomous AI Agents to drive innovation.
- Collaboration Growth
- How Evogene's ability to establish additional collaborations with leading biotechnology and pharmaceutical companies will impact its revenue growth.
Related topics